Eisai and Biogen Present New Data on LEQEMBI's Effectiveness in Reducing Neurotoxic Aβ Protofibrils in CSF.
ByAinvest
Tuesday, Dec 2, 2025 4:41 pm ET1min read
BIIB--
Eisai and Biogen presented data at the CTAD Conference 2025, confirming the pharmacological effect of LEQEMBI (lecanemab-irmb) on Aβ protofibrils in CSF. The study demonstrated that lecanemab binds to PF, mitigating their toxic effects and slowing Alzheimer's disease progression. The data showed a statistically significant increase in total CSF PF concentration with lecanemab treatment compared to placebo, and a correlation between PF changes and neurodegeneration biomarkers was observed in the placebo group but not with lecanemab treatment.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet